Concord Medical Services Holdings (CCM) EBITDA Margin (2009 - 2025)

Concord Medical Services Holdings (CCM) has 17 years of EBITDA Margin data on file, last reported at 72.1% in Q2 2025.

• Quarterly EBITDA Margin rose 1827.0% year-over-year to 72.1% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 95.54% (up 539.0% YoY) and the FY2025 annual result came in at 55.99%, up 8485.0% from the prior year.
• EBITDA Margin advanced to 72.1% in Q2 2025, from 90.37% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 72.1% in Q2 2025 to a low of 170.27% in Q2 2022.
• A 5-year average of 100.66% and a median of 90.37% in 2024 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2021 — EBITDA Margin soared 9737 bps — and 2022, when it sank 7492 bps.
• Tracing CCM's EBITDA Margin over 5 years: stood at 95.34% in 2021, then tumbled by 79 bps to 170.27% in 2022, then surged by 56 bps to 75.22% in 2023, then dropped by 20 bps to 90.37% in 2024, then increased by 20 bps to 72.1% in 2025.
• The last three EBITDA Margin figures came in at 72.1% (Q2 2025), 90.37% (Q2 2024), and 75.22% (Q2 2023), per Business Quant data.